Evidence map›Paper›PMID 37174081›Full record

ArticleCancers2023

Lymphovascular Space Invasion in Early-Stage Endometrial Cancer (LySEC): Patterns of Recurrence and Predictors. A Multicentre Retrospective Cohort Study of the Spain Gynecologic Oncology Group.

M Reyes Oliver-Perez, Pablo Padilla-Iserte, Octavio Arencibia-Sanchez, Cristina Martin-Arriscado, Juan Carlos Muruzabal, Berta Diaz-Feijóo, Silvia Cabrera, Pluvio Coronado, M Belen Martín-Salamanca, Manuel Pantoja-Garrido and 13 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 26 citations in OpenAlex.

  1. Improved prognostic stratification with the FIGO 2023 endometrial cancer staging system. A multicenter Spanish cohort study.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026
    Article
  2. AKR1B1 and AKR1B10 as Potential Prognostic Biomarkers of Endometrial Cancer.International journal of molecular sciences · 2026
    Article
  3. Review
  4. Lymphovascular space invasion is associated with increased locoregional recurrence despite adjuvant radiotherapy in node-negative stage I-II endometrioid endometrial cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Cancer of the corpus uteri: A 2025 update.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025
    Review
  13. Article
  14. Oncologic outcomes based on lymphovascular space invasion in node-negative FIGO 2009 stage I endometrioid endometrial adenocarcinoma: a multicenter retrospective cohort study.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2024
    Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 16 institutions in 1 country.

M Reyes Oliver-PerezGynecologic Oncology Unit, Department of Obstetrics and Gynecology, Hospital Universitario 12 de Octubre, 12 de Octubre Research Institute (i+12), 28041 Madrid, Spain.ORCID 0000-0003-3563-1825
Pablo Padilla-IserteDepartment of Gynaecologic Oncology, La Fe University and Polytechnic Hospital, 46026 Valencia, Spain.
Octavio Arencibia-SanchezDepartment of Gynecologic Oncology, University Hospital Materno-Infantil de Canarias, 35016 Las Palmas de Gran Canaria, Spain.ORCID 0000-0001-7352-8920
Cristina Martin-ArriscadoScientific Support Unit, Hospital Universitario 12 de Octubre, 12 de Octubre Research Institute (i+12), 28041 Madrid, Spain.ORCID 0000-0002-2147-2811
Juan Carlos MuruzabalDepartment of Gynecologic Oncology, Complejo Hospitalario de Navarra, 31008 Pamplona, Spain.
Berta Diaz-FeijóoInstitute Clinic of Gynecology, Obstetrics and Neonatology, Hospital Clinic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Universitat de Barcelona, 08036 Barcelona, Spain.ORCID 0000-0002-6451-1817
Silvia CabreraGynecologic Oncology Unit, Gynecology Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Pluvio CoronadoWomen's Health Institute of the Hospital Clínico San Carlos, IdISSC, School of Medicine, Complutense University Madrid, 28040 Madrid, Spain.ORCID 0000-0003-0357-2015
M Belen Martín-SalamancaDepartment of Gynecology, Hospital Universitario de Getafe, 28905 Madrid, Spain.ORCID 0000-0003-0207-8154
Manuel Pantoja-GarridoDepartment of Gynecology and Obstetrics, University Hospital Virgen Macarena, 41009 Sevilla, Spain.ORCID 0000-0001-8711-4083
Josefa Marcos-SanmartinDepartments of Obstetrics and Gynecology, Dr. Balmis General University Hospital, 03010 Alicante, Spain.ORCID 0000-0001-5907-8142
Elena Cabezas-LópezDepartment of Gynecologic Oncology, University Hospital Ramón y Cajal, 28034 Madrid, Spain.
Cristina LorenzoDepartment of Obstetrics and Gynecology, Hospital Nuestra Señora de la Calendaria, 38010 Santa Cruz de Tenerife, Spain.
Duska BericDepartment of Obstetrics and Gynecology, Hospital Universitario de Torrevieja, 03186 Alicante, Spain.
Jose Ramon Rodriguez-HernandezDepartment of Gynecology and Obstetrics, University Hospital Virgen de La Arrixaca, El Palmar, 30120 Murcia, Spain.ORCID 0000-0002-1943-1105
Fernando Roldan-RivasDepartment of Obstetrics and Gynaecology, Clinico Lozano Blesa Hospital, 50009 Zaragoza, Spain.
Juan Gilabert-EstellesDepartment of Pediatrics, Obstetrics and Gynecology, University General Hospital of Valencia, 46014 Valencia, Spain.
Lourdes SanchezDepartment of Gynecology and Obstetrics, University General Hospital of Ciudad Real, 13005 Ciudad Real, Spain.
Maria Laseca-ModregoDepartment of Gynecologic Oncology, University Hospital Materno-Infantil de Canarias, 35016 Las Palmas de Gran Canaria, Spain.ORCID 0000-0002-0777-3124
Carmen Tauste-RubioDepartment of Gynecologic Oncology, Complejo Hospitalario de Navarra, 31008 Pamplona, Spain.
Blanca Gil-IbañezGynecologic Oncology Unit, Department of Obstetrics and Gynecology, Hospital Universitario 12 de Octubre, 12 de Octubre Research Institute (i+12), 28041 Madrid, Spain.ORCID 0000-0002-0361-8741
Alvaro Tejerizo-GarciaGynecologic Oncology Unit, Department of Obstetrics and Gynecology, Hospital Universitario 12 de Octubre, 12 de Octubre Research Institute (i+12), 28041 Madrid, Spain.
On Behalf Of The Spain-Gog Group
Hospital Universitario 12 De Octubre · ESComplejo Hospitalario de Navarra · ESHospital Materno-Infantil · ESHospital Clínic de Barcelona · ESHospital Clínico San Carlos · ESHospital Clínico Universitario Lozano Blesa · ESHospital General Universitario De Valencia · ESHospital Quirón Torrevieja · ESHospital Universitari i Politècnic La Fe · ESHospital Universitario de Getafe · ESHospital Universitario Nuestra Señora de Candelaria · ESHospital Universitario Ramón y Cajal · ESHospital Universitario Virgen de la Arrixaca · ESHospital Universitario Virgen Macarena · ESUniversitat Autònoma de Barcelona · ESUniversitat de Miguel Hernández d'Elx · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The main aim is to compare oncological outcomes and patterns of recurrence of patients with early-stage endometrioid endometrial cancer according to lymphovascular space invasion (LVSI) status. The secondary objective is to determine preoperative predictors of LVSI. We performed a multicenter retrospective cohort study. A total of 3546 women diagnosed with postoperative early-stage (FIGO I-II, 2009) endometrioid endometrial cancer were included. Co-primary endpoints were disease-free survival (DFS), overall survival (OS), and pattern of recurrence. Cox proportional hazard models were used for time-to-event analysis. Univariate and multivariate logistical regression models were employed. Positive LVSI was identified in 528 patients (14.6%) and was an independent prognostic factor for DFS (HR 1.8), OS (HR 2.1) and distant recurrences (HR 2.37). Distant recurrences were more frequent in patients with positive LVSI (78.2% vs. 61.3%,

Indexed as

endometrial cancerLVSIlymphovascular space invasionrecurrencesurvival

Identifiers

PMID37174081
PMCPMC10177148
OpenAlexW4375842515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.